Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

: The novel agent pd-FVIIa/FX is a 1 : 10 protein weight mixture of activated factor VII (FVIIa) and factor X (FX) derived from donated blood plasma. A phase III clinical trial of pd-FVIIa/FX revealed high efficacy for bleeding episodes in haemophilia patients with inhibitors. However, up to now, only one case of this new agent being used for surgery had been reported. The objective of this study is to evaluate the perioperative haemostatic efficacy and safety of pd-FVIIa/FX in haemophilia patients with inhibitors. We retrospectively reviewed 25 operation charts from 14 haemophilia patients with high-responding inhibitors using pd-FVIIa/FX during the perioperative period. Efficacy was evaluated by attending physicians and results divided into four groups (excellent, good, fair, and poor). The operation chart was provided by nine Japanese medical institutes with expertise in haemophilia management. Out of the total of 25 surgical procedures, 44% (11/25) were classified as major surgery and the remainders were minor surgeries. In all of the surgeries but one, rFVIIa and/or APCC were administered in combination or sequential method. In all cases except one, the haemostatic efficiency rate was judged as excellent or good by treating physicians for an overall efficacy rate of 96%. No thrombotic adverse effects were reported. This study's results suggest that both combination and sequential therapy of pd-FVIIa/FX and other bypassing agents are well tolerated and effective for the control of perioperative bleeding in haemophilia patients with high-responding inhibitors.

[1]  Y. Ohashi,et al.  A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  J. Hirose,et al.  Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  H. Ju,et al.  The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors , 2015, Blood research.

[4]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[5]  M. Makris,et al.  Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  Tomoko Matsumoto,et al.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor , 2014, International Journal of Hematology.

[7]  Y. Ohashi,et al.  A Phase II clinical trial of a mixture of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics , 2013, Haemophilia.

[8]  A. Lienhart,et al.  SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  Y. Ohashi,et al.  Results of clot waveform analysis and thrombin generation test for a plasma‐derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors—phase I trial: 2nd report , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  Y. Ohashi,et al.  Clinical pharmacological study of a plasma‐derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors – Phase I trial , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Ingerslev,et al.  Parallel use of by‐passing agents in haemophilia with inhibitors: a critical review , 2011, British journal of haematology.

[12]  K. Fischer,et al.  Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  S. Rangarajan,et al.  Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  K. Kavaklı,et al.  Surgery in patients with haemophilia and high responding inhibitors: Izmir experience , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  V. Guérin,et al.  Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  N. Goddard,et al.  Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  E. Kraut,et al.  Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  V. Jiménez‐Yuste,et al.  Surgery in haemophilic patients with inhibitor: 20 years of experience , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  M. Shima,et al.  Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life‐threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  Y. Nakatomi,et al.  A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone , 2003, Vox sanguinis.